Latest News - Sanofi

Monday, September 18, 2017 | PracticalDermatology.com, Regeneron, Sanofi

EADV News: Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe AD

Dupixent with topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearing, itching, and patient reported quality of life measure in adults with moderate-to…

Read the full story

Friday, September 08, 2017 | PracticalDermatology.com, Regeneron, Sanofi

Cemiplimab Receives FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma

The FDA has granted Breakthrough Therapy designation status to Regeneron Pharmaceuticals, Inc. and Sanofi's cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamou…

Read the full story

Tuesday, March 28, 2017 | FDA Approval/Clearance, PracticalDermatology.com, Regeneron, Sanofi

FDA Approves New Eczema Drug Dupixent

The FDA has approved Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis). Regeneron Pharmaceuticals, Inc.'s Dupixent is intended for patients whose ec…

Read the full story

Wednesday, October 05, 2016 | PracticalDermatology.com, Atopic Derm, Atopic Dermatitis , National Eczema Association , Regeneron, Sanofi

New Survey: AD Is More Than Skin Deep

American adults with atopic dermatitis (AD) report issues with sleep, ability to work and feelings of depression and anxiety, a new survey shows. The findings are significant for clinicians, such as N…

Read the full story

Monday, October 03, 2016 | Phase 3/4 Trials, PracticalDermatology.com, Research and Publications, National Eczema Association , Regeneron, Sanofi

Regeneron and Sanofi's AD Drug Dupilumab Performs Well in Phase III Studies

Dupilumab improves the signs and symptoms of atopic dermatitis including pruritus, anxiety/depression symptoms, and quality of life, according to two Phase III clinical trials published in t…

Read the full story

Monday, September 26, 2016 | FDA Approval/Clearance, PracticalDermatology.com, Regeneron, Sanofi

Regeneron and Sanofi's Dupilumab Biologics License Application Accepted for Priority Review by FDA

The FDA has accepted for priority review the Biologics License Application (BLA) for dupilumab from Regeneron Pharmaceuticals, Inc. and Sanofi for the treatment of adult patients with inadequately con…

Read the full story

Monday, June 06, 2016 | Phase 3/4 Trials, PracticalDermatology.com, Regeneron, Sanofi

Dupilumab with Topical Corticosteroids (TCS) Superior to TCS Alone in Long-term Atopic Dermatitis Study

Treatment with investigational dupilumab in combination with topical corticosteroids (TCS) significantly improved measures of overall disease severity, according to one-year results of the LIBERTY AD …

Read the full story

Friday, April 01, 2016 | PracticalDermatology.com, Regeneron, Sanofi

Next Stop FDA Approval? Dupilumab Improves Symptoms in Moderate-to-Severe AD

Dupilumab helps improve the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adults, according to two late stage clinical trials. The U.S. Food and Drug Administration (FDA) grant…

Read the full story